DE60217186D1 - Dpiv-inhibitoren auf glutaminbasis - Google Patents
Dpiv-inhibitoren auf glutaminbasisInfo
- Publication number
- DE60217186D1 DE60217186D1 DE60217186T DE60217186T DE60217186D1 DE 60217186 D1 DE60217186 D1 DE 60217186D1 DE 60217186 T DE60217186 T DE 60217186T DE 60217186 T DE60217186 T DE 60217186T DE 60217186 D1 DE60217186 D1 DE 60217186D1
- Authority
- DE
- Germany
- Prior art keywords
- dpiv
- dpiv inhibitors
- sub
- glutamine
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36090902P | 2002-02-28 | 2002-02-28 | |
US360909P | 2002-02-28 | ||
PCT/EP2002/007124 WO2003072556A1 (en) | 2001-06-27 | 2002-06-27 | Glutaminyl based dpiv inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60217186D1 true DE60217186D1 (de) | 2007-02-08 |
DE60217186T2 DE60217186T2 (de) | 2007-09-27 |
Family
ID=23419891
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20220238U Expired - Lifetime DE20220238U1 (de) | 2002-02-28 | 2002-06-27 | Glutaminyl basierte DPIV Inhibitoren |
DE60217186T Expired - Fee Related DE60217186T2 (de) | 2002-02-28 | 2002-06-27 | Dpiv-inhibitoren auf glutaminbasis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20220238U Expired - Lifetime DE20220238U1 (de) | 2002-02-28 | 2002-06-27 | Glutaminyl basierte DPIV Inhibitoren |
Country Status (27)
Country | Link |
---|---|
US (2) | US6946480B2 (de) |
EP (1) | EP1480961B1 (de) |
JP (1) | JP2005527504A (de) |
KR (1) | KR20040095241A (de) |
CN (1) | CN1622941A (de) |
AT (1) | ATE349435T1 (de) |
AU (1) | AU2002325278A1 (de) |
BG (1) | BG108857A (de) |
BR (1) | BR0215622A (de) |
CA (1) | CA2479812A1 (de) |
CZ (1) | CZ2004973A3 (de) |
DE (2) | DE20220238U1 (de) |
DK (1) | DK1480961T3 (de) |
EA (1) | EA007434B1 (de) |
ES (1) | ES2278944T3 (de) |
HK (1) | HK1067120A1 (de) |
HU (1) | HUP0600057A2 (de) |
IL (1) | IL163629A0 (de) |
MX (1) | MXPA04008278A (de) |
NO (1) | NO20044038L (de) |
NZ (1) | NZ534877A (de) |
PL (1) | PL372316A1 (de) |
PT (1) | PT1480961E (de) |
SI (1) | SI1480961T1 (de) |
SK (1) | SK3622004A3 (de) |
UA (1) | UA76309C2 (de) |
ZA (1) | ZA200406813B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200000815T2 (tr) * | 1997-09-29 | 2000-12-21 | Point Therapeutics Inc. | In vitro hematopoietik hücrelerin stimulasyonu. |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US20070293426A1 (en) * | 2001-04-02 | 2007-12-20 | Hans-Ulrich Demuth | Methods for improving islet signaling in diabetes mellitus and for its prevention |
ES2296962T3 (es) * | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Pirrolidinas como inhibidores de dipeptidil peptidasa. |
CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1663200A2 (de) * | 2003-09-02 | 2006-06-07 | Prosidion Limited | Kombinationstherapie für die blutzuckerkontrolle |
EP1699777B1 (de) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidylpeptidase-hemmer |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GEP20094679B (en) | 2004-03-15 | 2009-05-10 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors |
JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
CA2574418A1 (en) * | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
EP2805953B1 (de) * | 2004-12-21 | 2016-03-09 | Takeda Pharmaceutical Company Limited | Dipeptidyl-Peptidase-Hemmer |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
AP2007004234A0 (en) | 2005-04-22 | 2007-12-31 | Alantos Pharm Holding | Dipeptidyl peptidase-IV inhibitors |
GEP20135838B (en) | 2005-09-14 | 2013-06-10 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors usage at diabetes treatment |
CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN1979367B (zh) * | 2005-11-30 | 2013-05-15 | 北京中电华大电子设计有限责任公司 | 采用测试校准提高器件参数精度的方法 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
NZ571110A (en) | 2006-04-11 | 2011-03-31 | Arena Pharm Inc | Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2146210A1 (de) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden |
SG174974A1 (en) * | 2009-03-30 | 2011-11-28 | Dong A Pharm Co Ltd | Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
CN102453001B (zh) * | 2010-10-22 | 2016-06-01 | 中国医学科学院药物研究所 | 硫代吗啉类化合物及其制备方法和用途 |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE296075C (de) | ||||
US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3879541A (en) | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
DE2009743A1 (de) | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituierte Biguanide mit antihyperglykämischer Wirkung |
US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
CH602612A5 (de) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
DD296075A5 (de) * | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
DK0512042T3 (da) | 1990-01-24 | 1998-05-11 | Douglas I Buckley | GLP-1-analoger anvendelige ved diabetesbehandling |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
EP0528858B1 (de) | 1990-04-14 | 1997-01-22 | New England Medical Center Hospitals, Inc. | Typ-iv-dipeptidyl-aminopeptidase-inhibitoren |
WO1991017767A1 (en) | 1990-05-21 | 1991-11-28 | New England Medical Center Hospitals, Inc. | Method of treating inhibition of dipeptidyl aminopeptidase type iv |
JPH0819154B2 (ja) | 1991-03-14 | 1996-02-28 | 江崎グリコ株式会社 | ジペプチジルカルボキシペプチダーゼを阻害するペプチド |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
ATE199016T1 (de) | 1991-10-22 | 2001-02-15 | New England Medical Center Inc | Inhibitoren der dipeptidyl-aminopeptidase vom typ-iv |
IL106998A0 (en) | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
FR2696740B1 (fr) | 1992-10-13 | 1994-12-30 | Dospharma Sa | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. |
WO1995011689A1 (en) | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
AU3224997A (en) | 1996-05-29 | 1998-01-05 | Prototek, Inc | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
WO1999046272A1 (en) | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Serine peptidase modulators |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
PT1084129E (pt) | 1998-06-05 | 2003-06-30 | Point Therapeutics Inc | Compostos de boroprolina ciclica |
DE19826972A1 (de) | 1998-06-18 | 1999-12-23 | Univ Magdeburg Tech | Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation |
AU4854999A (en) | 1998-07-02 | 2000-01-24 | Invitro Diagnostics, Inc. | Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule |
DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
IL141471A0 (en) | 1998-08-21 | 2002-03-10 | Point Therapeutics Inc | Regulation of substrate activity |
WO2000053171A1 (en) | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
WO2001062266A2 (en) | 2000-02-25 | 2001-08-30 | Novo Nordisk A/S | Use of dpp-iv inhibitors for the treatment of diabetes |
PT2055302E (pt) | 2000-03-31 | 2014-12-03 | Royalty Pharma Collection Trust | Processo para a melhoria da sinalização de ilhéus em diabetes mellitus e para a sua prevenção |
US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
DE10025464A1 (de) | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7785810B2 (en) | 2000-09-09 | 2010-08-31 | The Research Foundation Of State University Of New York | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
CA2424964C (en) * | 2000-10-06 | 2007-12-04 | Tanabe Seiyaku Co., Ltd. | Nitrogen-containing 5-membered ring compound |
-
2002
- 2002-06-27 AU AU2002325278A patent/AU2002325278A1/en not_active Abandoned
- 2002-06-27 AT AT02758280T patent/ATE349435T1/de not_active IP Right Cessation
- 2002-06-27 DE DE20220238U patent/DE20220238U1/de not_active Expired - Lifetime
- 2002-06-27 PT PT02758280T patent/PT1480961E/pt unknown
- 2002-06-27 PL PL02372316A patent/PL372316A1/xx not_active Application Discontinuation
- 2002-06-27 UA UA20040907210A patent/UA76309C2/uk unknown
- 2002-06-27 NZ NZ534877A patent/NZ534877A/en unknown
- 2002-06-27 IL IL16362902A patent/IL163629A0/xx unknown
- 2002-06-27 BR BR0215622-9A patent/BR0215622A/pt not_active IP Right Cessation
- 2002-06-27 CN CNA028284070A patent/CN1622941A/zh active Pending
- 2002-06-27 KR KR10-2004-7013493A patent/KR20040095241A/ko not_active Application Discontinuation
- 2002-06-27 SI SI200230479T patent/SI1480961T1/sl unknown
- 2002-06-27 JP JP2003571262A patent/JP2005527504A/ja active Pending
- 2002-06-27 DK DK02758280T patent/DK1480961T3/da active
- 2002-06-27 CZ CZ2004973A patent/CZ2004973A3/cs unknown
- 2002-06-27 DE DE60217186T patent/DE60217186T2/de not_active Expired - Fee Related
- 2002-06-27 CA CA002479812A patent/CA2479812A1/en not_active Abandoned
- 2002-06-27 EA EA200401062A patent/EA007434B1/ru not_active IP Right Cessation
- 2002-06-27 MX MXPA04008278A patent/MXPA04008278A/es active IP Right Grant
- 2002-06-27 EP EP02758280A patent/EP1480961B1/de not_active Expired - Lifetime
- 2002-06-27 HU HU0600057A patent/HUP0600057A2/hu unknown
- 2002-06-27 ES ES02758280T patent/ES2278944T3/es not_active Expired - Lifetime
- 2002-06-27 SK SK362-2004A patent/SK3622004A3/sk unknown
- 2002-09-16 US US10/244,347 patent/US6946480B2/en not_active Expired - Fee Related
-
2004
- 2004-02-13 US US10/779,158 patent/US7060719B2/en not_active Expired - Lifetime
- 2004-08-25 BG BG108857A patent/BG108857A/xx unknown
- 2004-08-26 ZA ZA200406813A patent/ZA200406813B/xx unknown
- 2004-09-24 NO NO20044038A patent/NO20044038L/no not_active Application Discontinuation
- 2004-12-18 HK HK04110052A patent/HK1067120A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BG108857A (en) | 2005-12-30 |
CN1622941A (zh) | 2005-06-01 |
MXPA04008278A (es) | 2005-09-20 |
DE20220238U1 (de) | 2003-05-08 |
US6946480B2 (en) | 2005-09-20 |
UA76309C2 (en) | 2006-07-17 |
SI1480961T1 (sl) | 2007-06-30 |
AU2002325278A1 (en) | 2003-09-09 |
EA007434B1 (ru) | 2006-10-27 |
JP2005527504A (ja) | 2005-09-15 |
PT1480961E (pt) | 2007-02-28 |
US7060719B2 (en) | 2006-06-13 |
ATE349435T1 (de) | 2007-01-15 |
CZ2004973A3 (cs) | 2004-12-15 |
NO20044038L (no) | 2004-09-28 |
DE60217186T2 (de) | 2007-09-27 |
ZA200406813B (en) | 2006-06-28 |
SK3622004A3 (sk) | 2005-02-04 |
CA2479812A1 (en) | 2003-09-04 |
NZ534877A (en) | 2006-05-26 |
HUP0600057A2 (en) | 2006-05-29 |
KR20040095241A (ko) | 2004-11-12 |
ES2278944T3 (es) | 2007-08-16 |
IL163629A0 (en) | 2005-12-18 |
US20040167191A1 (en) | 2004-08-26 |
DK1480961T3 (da) | 2007-05-07 |
EP1480961A1 (de) | 2004-12-01 |
PL372316A1 (en) | 2005-07-11 |
BR0215622A (pt) | 2004-12-07 |
EP1480961B1 (de) | 2006-12-27 |
HK1067120A1 (en) | 2005-04-01 |
US20030162820A1 (en) | 2003-08-28 |
EA200401062A1 (ru) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60217186D1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
NO20030896L (no) | Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler | |
MY142915A (en) | Rho-kinase inhibitors | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
DE60318177D1 (de) | Rho-kinase inhibitoren | |
ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
ATE440087T1 (de) | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen | |
ATE361300T1 (de) | Derivate von heteroarylnitrilverbindungen | |
DE60330895D1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
GB0121033D0 (en) | Organic compounds | |
TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
MXPA05009535A (es) | Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos. | |
EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
ITMI20031311A1 (it) | Formulazioni per il trattamento di disturbi artrosici. | |
WO2003106450A8 (de) | Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren | |
ES2333026T3 (es) | Derivados de ciclohexil-1,4-diamina sustituidos. | |
ATE501128T1 (de) | 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion | |
MXPA05007607A (es) | Inhibidores amida y ester de la metaloproteinasa de matriz. | |
DK1362045T3 (da) | 2-Thio-substituerede imidazolderivater og deres anvendelse inden for farmacien | |
BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
ATE373658T1 (de) | Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase | |
UA86051C2 (en) | Substituted quinoline compounds | |
RS20050421A (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
MY141048A (en) | Morpholine derivatives as norepinephrine reuptake inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |